Assessing QT interval in COVID-19 patients: Safety of Hydroxychloroquine-azithromycin combination regimen
Hydroxychloroquine (HCQ) and azithromycin (AZT) have been proposed for COVID-19 treatment. Data available in the literature reported a potential increased risk of fatal arrhythmias under these therapies. The aim of this study was to assess the effects of these drugs on QT interval and outcome in a COVID-19 population.
Source: International Journal of Cardiology - Category: Cardiology Authors: Andrea Bernardini, Giuseppe Ciconte, Gabriele Negro, Roberto Rondine, Valerio Mecarocci, Tommaso Viva, Francesca Santini, Carlo de Innocentiis, Luigi Giannelli, Ewa Witkowska, Emanuela Teresina Locati, Serenella Castelvecchio, Massimiliano Marrocco-Trisch Source Type: research
More News: Arrhythmia | Azithromycin | Cardiology | COVID-19 | Heart | Hydroxychloroquine | Study | Zithromax